Page last updated: 2024-10-31

mitoxantrone and Genito-urinary Cancer

mitoxantrone has been researched along with Genito-urinary Cancer in 1 studies

Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.

Research Excerpts

ExcerptRelevanceReference
"Reported response rates of transitional cell carcinoma (TCC) in dogs to piroxicam in combination with either mitoxantrone or carboplatin are similar; however, it is unknown whether either drug might provide superior duration of response."2.80Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs. ( Allstadt, SD; Boostrom, B; Rebhun, RB; Rodriguez, CO; Skorupski, KA, 2015)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Allstadt, SD1
Rodriguez, CO1
Boostrom, B1
Rebhun, RB1
Skorupski, KA1

Trials

1 trial available for mitoxantrone and Genito-urinary Cancer

ArticleYear
Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs.
    Journal of veterinary internal medicine, 2015, Volume: 29, Issue:1

    Topics: Animals; Antineoplastic Agents; Carboplatin; Carcinoma, Transitional Cell; Dog Diseases; Dogs; Drug

2015